Umeclidinium Bromide 62.5 mcg Suppliers & Bulk Manufacturers

Available Forms: dry-powder inhaler

Available Strengths: 62.5 mcg

Reference Brands: Incruse Ellipta (USA)

Category: Respiratory Disorder

Umeclidinium bromide is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of COPD. By blocking muscarinic receptors (especially M3) in airway smooth muscle, it causes bronchodilation and helps improve airflow. It is given once daily via a dry-powder inhaler, making it convenient for long-term therapy. Clinical trials have shown that it provides sustained lung function improvement and is generally well tolerated, with a low risk of systemic anticholinergic side effects.

Product Description:

Umeclidinium bromide is a long-acting muscarinic antagonist for once-daily maintenance treatment of COPD, blocking M3 receptors on airway smooth muscle to produce sustained bronchodilation. It is delivered at 62.5 mcg through a dry-powder inhaler, and is also supplied in fixed combination with vilanterol, a long-acting beta-2 agonist, and in triple combination with fluticasone furoate.

Anticholinergic bronchodilators are generally better tolerated than beta-2 agonists in older COPD patients, avoiding tremor and tachycardia, though dry mouth is common and caution applies in narrow-angle glaucoma and bladder outflow obstruction.

Sourcing notes. This is a device-dependent product and the device is proprietary. The dry-powder inhaler is not a generic component that can be substituted, which materially constrains generic entry even where the molecule's patent position has weakened — a recurring feature of the inhaled market, where device intellectual property frequently outlasts compound patents. Verify the patent and device position in the destination market before treating this as a genericisable product.

Where the requirement is once-daily LAMA maintenance therapy rather than umeclidinium specifically, tiotropium has wider generic availability and longer registration precedent across most markets, and is usually the more practical answer to a bulk sourcing enquiry.